Prescribing cascades don’t usually start with “bad” medications. In fact, they often begin with some of our most effective therapies. Metformin, SGLT2 inhibitors, and GLP-1 receptor agonists all have strong outcome data in type 2 diabetes. But when adverse effects are...
Ertugliflozin was first approved in 2017 for the treatment of type 2 diabetes. This medication is an SGLT2 inhibitor that prevents the resorption of glucose back into systemic circulation. It has been shown to be effective in lowering A1c and managing diabetes. In...
Diabetic Ketoacidosis (DKA) is traditionally characterized by the triad of hyperglycemia, metabolic acidosis, and ketoacidosis. However, approximately 3% of DKA cases are caused by Euglycemic DKA (EDKA). In the past, this percentage was significantly lower, but the...
A few months back, I compared one of the newest SGLT2 inhibitors in bexagliflozin to the other agents in this class of medication. To sum up my analysis, bexagliflozin provided nothing significantly different from the other SGLT2 inhibitors. In fact, it has less...
As a geriatric pharmacist, I’m always on high alert for the prescribing cascade. I outline my top 5 examples of the prescribing cascade in diabetes care in this article. Metformin and Loperamide Metformin has been the go-to first-line agent of choice for years....
